Pirfenidone D5 is a penta-deuterated form and metabolite of Pirfenidone. Pirfenidone (S7701, AMR-69; AMR69; S-7701; Pirespa; Pirfenex; Deskar, Esbriet) is a potent inhibitor for TGF-β production and TGF-β stimulated collagen production and has been approved for the treatment of idiopathic pulmonary fibrosis.
Physicochemical Properties
| Molecular Formula | C12H6D5NO |
| Molecular Weight | 190.2527 |
| Exact Mass | 190.115 |
| CAS # | 1020719-62-3 |
| Related CAS # | Pirfenidone;53179-13-8;Deupirfenidone-d3;1093951-85-9 |
| PubChem CID | 71434117 |
| Appearance | White to light yellow solid powder |
| LogP | 2.145 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 1 |
| Heavy Atom Count | 14 |
| Complexity | 285 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | [2H]C1=C(C(=C(C(=C1[2H])[2H])N2C=C(C=CC2=O)C)[2H])[2H] |
| InChi Key | ISWRGOKTTBVCFA-VIQYUKPQSA-N |
| InChi Code | InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3/i2D,3D,4D,5D,6D |
| Chemical Name | 5-methyl-1-(2,3,4,5,6-pentadeuteriophenyl)pyridin-2-one |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References |
[1]. Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun. 2007 Mar 9;354(2):542-7. [2]. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. 2002 Jun 20;446(1-3):177-85. [3]. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir Res. 2014 Feb 8;15:16. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~525.62 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (32.85 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 6.25 mg/mL (32.85 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL corn oil and mix evenly. Solubility in Formulation 3: ≥ 5.95 mg/mL (31.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 59.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2562 mL | 26.2812 mL | 52.5624 mL | |
| 5 mM | 1.0512 mL | 5.2562 mL | 10.5125 mL | |
| 10 mM | 0.5256 mL | 2.6281 mL | 5.2562 mL |